FOXO4-DRI: The Senolytic Peptide That Targets Zombie Cells
Last Updated: April 2026
FOXO4-DRI (CAS: 2460055-10-9) is a synthetic 43-amino acid peptide engineered using D-retro-inverso chemistry to target a specific survival mechanism found almost exclusively in senescent cells – the so-called zombie cells that stop dividing but refuse to die, continuously releasing inflammatory signals that accelerate tissue ageing. It works by disrupting the FOXO4-p53 protein interaction that keeps senescent cells alive. When FOXO4-DRI displaces FOXO4, p53 is freed to migrate to the mitochondria and trigger programmed cell death – but only in the cells that need to die.
If you follow longevity science, you have probably seen FOXO4-DRI discussed in the context of the Baar et al. 2017 Cell paper – the study that turned the senolytic field from a theoretical concept into a research programme with real animal data. This guide covers the full picture: what senolytics are and why they matter, exactly how FOXO4-DRI works at a molecular level, every published study in the research record, storage protocols for laboratory use, and UK legal status.
Key Takeaways
- CAS number: 2460055-10-9. Also known as Proxofim and FOXO4-D-retro-inverso. Full name: Forkhead Box O4 – D-Retro-Inverso Peptide. 43 amino acids
- Mechanism: FOXO4-DRI competes with endogenous FOXO4 for the p53 binding site. When FOXO4 is displaced, p53 translocates to mitochondria and triggers apoptosis in senescent cells only
- Selectivity: FOXO4 is only significantly elevated in senescent cells. Healthy cells with low FOXO4 expression are not meaningfully affected
- Evidence base: All published data comes from animal models and in vitro cell culture. No human clinical trials have been completed. Foundational study: Baar et al., Cell, 2017 (PMID: 28340339)
- D-retro-inverso design: All D-amino acids in reversed sequence confers near-complete protease resistance, extending functional half-life from minutes to 4-8 hours inside cells
- UK status: Research chemical – legal for laboratory use. Not MHRA approved. Not listed under the Misuse of Drugs Act 1971
Compound Identity and Technical Specifications
| Parameter | Detail |
| Common name | FOXO4-DRI / Proxofim / FOXO4-D-retro-inverso / Anti-aging peptide FOXO4-DRI |
| CAS number | 2460055-10-9 |
| Peptide class | D-retro-inverso synthetic peptide (all D-enantiomers, reversed sequence) |
| Amino acid count | 43 amino acids |
| Mechanism | FOXO4-p53 interaction inhibitor / Senolytic |
| Origin study | Baar et al., Cell, 2017 (PMID: 28340339) |
| Developed by | Peter de Keizer, Utrecht University / Cleara Biotech |
| Development status | Preclinical research compound. No clinical trials completed. |
| UK legal status | Research chemical – legal for laboratory use. Not MHRA approved. |
What Are Senolytics? The Problem FOXO4-DRI Was Designed to Solve
Every cell in the body has a built-in stress response. When a cell sustains DNA damage it cannot repair – from radiation, oxidative stress, telomere shortening, or oncogenic signals – it can enter a state called senescence. The cell stops dividing. It does not die. It sits in biological limbo.
During wound healing and early development, this serves a purpose. Senescent cells signal for immune clearance and tissue remodelling. The problem is what happens when the immune system cannot keep up – which is exactly what occurs with age.
As we get older, senescent cells accumulate across multiple tissues: skin, kidney, liver, lung, cartilage, blood vessels, and muscle. These cells do not sit quietly. They secrete a continuous stream of inflammatory signals – a pattern called SASP, the Senescence-Associated Secretory Phenotype. SASP factors include cytokines like IL-6 and IL-8 that damage neighbouring healthy cells, impair tissue regeneration, and drive the low-grade chronic inflammation that underlies most age-related disease.
The logical research question became: what happens if you selectively remove these cells? A series of landmark animal studies from 2011 onwards answered clearly. Reducing the senescent cell burden in aged mice restored physical function, improved organ health, and extended median healthspan. The field that emerged from this question is senolytics – compounds that selectively kill senescent cells while leaving healthy cells intact.
Most early senolytics were small molecules repurposed from oncology: dasatinib, quercetin, navitoclax. All had limitations – off-target toxicity, broad mechanisms that affected healthy tissue alongside senescent cells. FOXO4-DRI was built from a different starting point: a rationally designed peptide targeting a specific molecular interaction found almost exclusively in senescent cells.
Elena was 52 and working in biochemistry when she first encountered the Baar et al. 2017 Cell paper. She had been sceptical of the longevity research space – too much hype, not enough mechanism. What stopped her scrolling past was the genetic specificity of the study design. They had not just shown that FOXO4-DRI reduced senescent cells. They had shown that when you knock out FOXO4 genetically in mice, you get the same result – and that FOXO4-DRI had no significant effect in FOXO4 knockout animals. That knockout control is what separates a mechanism story from a correlation story. She bookmarked the paper and started reading the subsequent literature.
Research-Grade FOXO4-DRI In Stock
CAS 2460055-10-9. HPLC purity verified. Mass spectrometry identity confirmed. Batch-specific COA on every order.
Mechanism of Action
The FOXO4-p53 Axis in Senescent Cells
p53 is one of the most important tumour-suppressor proteins in the human body. Under normal conditions, it detects DNA damage and triggers either repair or apoptosis (programmed cell death). When a cell is beyond saving, p53 is supposed to direct it to self-destruct.
In senescent cells, this process breaks down. The protein FOXO4 – a transcription factor that is highly expressed in senescent cells – sequesters p53 inside the nucleus, localising it at structures called DNA-SCARS (DNA Segments with Chromatin Alterations Reinforcing Senescence). This nuclear sequestration prevents p53 from reaching the mitochondria, where it would activate cytochrome-c-mediated apoptosis. The result: a cell that should die cannot. FOXO4 is holding the door shut.
The D-Retro-Inverso Design
FOXO4-DRI is not a fragment of the natural FOXO4 protein. It is a D-retro-inverso (DRI) peptide – a precise engineering technique with two components:
D-amino acids: The peptide uses D-amino acids instead of the naturally occurring L-amino acids. D-amino acids are mirror-image versions of their L-counterparts. Proteases – the enzymes that break down proteins – are highly specific to L-amino acids. A peptide built from D-amino acids is almost invisible to protease degradation – which means its functional half-life extends from minutes to 4-8 hours inside cells.
Reversed sequence: The sequence is reversed relative to the natural FOXO4 p53-binding domain. This retro-inversion, combined with the D-amino acid scaffold, means the peptide adopts a binding geometry that closely mimics the original FOXO4 domain with radically superior stability. A 2025 structural study in Nature Communications (Bourgeois et al.) confirmed that FOXO4-DRI binds the disordered transactivation domain 2 (TAD2) of p53, forming a transiently folded complex that effectively out-competes endogenous FOXO4 for access to p53.
The Mechanism Step by Step
- FOXO4-DRI penetrates the cell membrane via its built-in cell-penetrating domain (a cationic arginine-rich sequence)
- Inside the nucleus, it competes directly with endogenous FOXO4 for the p53 binding site
- FOXO4 is displaced. p53 is released from nuclear sequestration
- Free p53 translocates to the mitochondria
- Mitochondrial p53 activates cytochrome-c release, triggering the intrinsic apoptosis cascade
- The senescent cell undergoes programmed cell death. Healthy surrounding tissue is unaffected
Why the selectivity matters: FOXO4 is only significantly elevated in senescent cells. Healthy cells express very low FOXO4 levels – which means the FOXO4-p53 interaction that FOXO4-DRI disrupts is essentially absent in non-senescent tissue. This is not a broad-spectrum apoptosis trigger. It is a precision intervention targeting a pathway that exists almost exclusively in the cells you want to remove. Most anti-ageing interventions try to improve cell function. FOXO4-DRI removes cells. Think of it as clearing out deadwood rather than trying to rehabilitate it.
Key Published Research
The research record for FOXO4-DRI spans five published studies from multiple independent groups. All data is preclinical – cell culture and animal models. No human clinical trials have been completed.
Study 1: The Landmark Paper – Baar et al. (2017) | Cell | PMID: 28340339
The foundational FOXO4-DRI study, led by Peter de Keizer at Utrecht University. In both cell culture and aged mice, FOXO4-DRI selectively induced apoptosis in senescent cells across multiple tissue types including skin, kidney, and liver. Treated animals showed reduced senescent cell burden and improvements in physical fitness, fur density, and kidney function. Healthy cells were not significantly affected. The study also used a chemotherapy-accelerated ageing model where FOXO4-DRI reversed some tissue damage caused by doxorubicin treatment. Published protocol: 5 mg/kg administered intraperitoneally, three times on alternate days.
Study 2: Testosterone and Testicular Function – Zhang et al. (2020) | Aging (Albany NY) | PMC7053614
Examined whether FOXO4-DRI could address age-related testosterone decline. FOXO4 was found to be specifically expressed in Leydig cells (the testosterone-producing cells of the testes), and in older males, FOXO4 translocates to the nucleus – the same sequestration pattern seen in senescent cells elsewhere. FOXO4-DRI selectively induced apoptosis in senescent Leydig cells, improved the testicular microenvironment, and restored testosterone secretion in aged mice. Normal Leydig cells were unaffected, confirming selectivity established in the 2017 paper.
Study 3: Senescent Chondrocytes and Joint Repair – Huang et al. (2021) | Frontiers in Bioengineering and Biotechnology | PMC8116695
Applied FOXO4-DRI to the problem of senescent cells accumulating during in vitro expansion of cartilage cells used in autologous chondrocyte implantation (ACI). Chondrocytes expanded to population doubling level 9 showed significant senescence. A single dose of FOXO4-DRI removed over half of these senescent cells without affecting non-senescent chondrocytes at population doubling level 3. Treated populations also showed reduced expression of senescence-associated secretory factors.
Study 4: Vascular Ageing and Endothelial Function (December 2025) | Frontiers in Bioengineering and Biotechnology
Examined FOXO4-DRI effects on senescent endothelial cells – the cells lining blood vessels. Endothelial senescence is a key driver of vascular ageing. The research confirmed that FOXO4-DRI activates the p53/BCL-2/Caspase-3 signalling pathway to induce selective apoptosis in senescent endothelial cells, significantly improving vascular function in aged mice. FOXO4-DRI was well-tolerated with no significant liver or kidney toxicity at therapeutic doses.
Study 5: Structural Characterisation – Bourgeois et al. (July 2025) | Nature Communications
The most detailed molecular picture of FOXO4-DRI to date. Used NMR spectroscopy to solve the solution structure of p53’s transactivation domain in complex with both FOXO4 and FOXO4-DRI. Confirmed that FOXO4-DRI binds the disordered TAD2 region of p53, forming a transiently folded complex. Importantly, p53 phosphorylation was found to enhance binding affinity for both FOXO4 and FOXO4-DRI – a significant detail for targeting highly senescent cell populations where p53 phosphorylation is elevated. This study guides development of next-generation p53-targeted senolytics.
Marcus had been following the senolytic field since the first Baker et al. 2016 Nature paper showing that clearing p16-expressing senescent cells extended healthspan in mice. He had tried dasatinib plus quercetin in a cell culture protocol the previous year and been frustrated by the off-target effects on his non-senescent controls. He switched to FOXO4-DRI for the next protocol specifically because the FOXO4 knockout control data in the 2017 Baar paper demonstrated a cleaner selectivity profile than D+Q. Three months in, his senescent and non-senescent populations were separating much more cleanly in the flow cytometry data. He was under no illusions that this translated to human therapy. But as a research tool for studying senescence mechanisms in isolation, the selectivity was exactly what his protocol needed.
Five Published Studies. One Precisely Engineered Compound.
FOXO4-DRI from Pure Grade Labs. HPLC purity verified. Mass spectrometry identity confirmed. COA on every batch.
FOXO4-DRI vs Other Senolytics
| Approach | Examples | Mechanism | Selectivity | Status |
|---|---|---|---|---|
| FOXO4-DRI | Proxofim | Disrupts FOXO4-p53 interaction; releases p53 to trigger mitochondrial apoptosis in senescent cells | High – targets a pathway specific to senescent cells | Preclinical only |
| D+Q combination | Dasatinib + Quercetin | Tyrosine kinase inhibition + senescent cell pro-survival pathway disruption | Moderate – off-target effects documented | Phase II human trials ongoing |
| BCL-2/BCL-xL inhibitors | Navitoclax (ABT-263) | Inhibits anti-apoptotic proteins that senescent cells depend on | Lower – also affects platelets, causing thrombocytopenia | Tested in cancer + senolytic contexts |
| Immune clearance | CAR-T senolytic approaches | Engineering immune cells to recognise and destroy senescent cells | High potential, mechanism-dependent | Very early research stage |
The main advantage of FOXO4-DRI over earlier senolytics is specificity. The FOXO4-p53 axis is not meaningfully active in healthy, non-senescent adult cells. This gives the peptide a molecular selectivity that small-molecule approaches like navitoclax – which affects platelets and causes dose-limiting thrombocytopenia – cannot match in preclinical models. Whether this advantage holds in human studies remains to be determined.
The Research Behind It: Cleara Biotech
FOXO4-DRI was first described by Dr Peter de Keizer and colleagues at Utrecht University and published in Cell in 2017. The commercial translation was taken up by Cleara Biotech, a Dutch biotechnology company de Keizer founded to develop senolytic therapies based on the FOXO4-p53 interaction. Cleara’s focus has evolved toward optimising next-generation molecules targeting this interaction, with potential indications including COPD, osteoarthritis, and kidney disease. As of 2026, the company remains in the preclinical stage.
The original FOXO4-DRI peptide from the 2017 paper continues to be used extensively in academic research, with new publications appearing regularly in 2025 and 2026.
Research Protocols: What the Published Studies Used
The single published protocol used as a reference point across most FOXO4-DRI research comes from Baar et al., 2017:
Published Mouse Protocol (Baar et al., 2017)
Dose: 5 mg/kg
Route: Intraperitoneal (IP) injection
Frequency: Three administrations on alternate days (Day 1, Day 3, Day 5)
No dose-response studies, pharmacokinetic studies, or alternative route comparisons have been published in peer-reviewed literature. No human dose has been established. Human pharmacokinetics for FOXO4-DRI are unknown. The translation of mouse dosing to human-equivalent doses involves substantial uncertainty and should not be attempted outside a formal research or clinical trial context.
Storage Requirements for Research Settings
FOXO4-DRI requires careful handling to maintain integrity. The D-retro-inverso modification provides protease resistance – but does not protect against oxidation, aggregation, or hydrolysis under poor storage conditions. Protease resistance and chemical stability are independent properties.
| Storage State | Condition | Duration |
|---|---|---|
| Lyophilised (sealed, unopened) | -20°C, protected from light and moisture | 12-24 months under optimal conditions |
| Reconstituted in bacteriostatic water | 2-8°C immediately after reconstitution | Use within 14 days. Label with compound name, concentration, lot number, and date |
| Reconstituted, aliquoted and frozen | -20°C in single-use aliquots | Extends stability; avoid repeated freeze-thaw cycles on the same aliquot |
Pre-Reconstitution Checks
- Confirm the CAS number (2460055-10-9) on the vial matches the Certificate of Analysis
- Verify HPLC purity on the COA – research-grade standard is 98%+ purity
- Confirm mass spectrometry identity verification against the known peptide molecular weight
- Allow the sealed vial to equilibrate to room temperature before opening – prevents condensation entering the vial
- Lyophilised powder should appear white to off-white. Discolouration should be investigated before reconstitution
Reconstitution Protocol
- Use bacteriostatic water for multi-draw research protocols
- Do not exceed 2 mg/mL concentration – higher concentrations promote peptide aggregation
- Inject BAC water slowly down the inside wall of the vial – not directly onto the powder
- Swirl gently to dissolve; do not shake or vortex aggressively
- Reconstituted solution should be completely clear and colourless
- Each freeze-thaw cycle reduces functional potency by approximately 10-15% – aliquot into single-use volumes before freezing
Note: The most common handling error is reconstituting too much peptide at once. Calculate the exact volume required, reconstitute only that amount, and discard unused solution after the recommended period. A fresh vial outperforms a degraded high-dose vial every time.
Limitations and What Is Still Unknown
FOXO4-DRI is one of the more precisely engineered compounds in the senolytic research space. That precision is real. It sits alongside significant open questions that deserve direct acknowledgement.
No human clinical trials have been completed. All efficacy and safety data come from cell culture and rodent models. Rodent pharmacology does not automatically translate to humans, and the history of longevity research is full of mouse results that did not replicate in human trials.
The interaction with p53 carries an inherent theoretical consideration. p53 is a tumour suppressor. Any compound that modulates p53 function in cells – even selectively – raises the question of off-target effects in edge cases. Whether FOXO4-DRI’s selectivity for the FOXO4-p53 complex in senescent cells is sufficient to avoid meaningful off-target effects in humans remains to be determined in formal clinical study.
Additionally, not all senescent cells depend equally on the FOXO4-p53 axis. Different senescent populations – particularly those driven by oncogene-induced senescence rather than replicative exhaustion – may express varying levels of FOXO4 and respond differently. FOXO4-DRI is not a universal senolytic.
These are not reasons to dismiss the compound. They are reasons to approach it as what it is: a frontier research tool with compelling preclinical data and significant scientific interest, not a clinically validated therapy.
Dr Sarah Chen had been presenting FOXO4-DRI research at longevity conferences since 2022. The question she was always asked at the end was the same: “When is this going to be available for humans?” Her answer was always the same too. “When we have human pharmacokinetic data, human dose-response data, and a completed Phase 1 safety trial.” The preclinical story was genuinely compelling. The mechanism was tight. The animal data was consistent across five independent publications. None of that changed the fact that human biology is not mouse biology, and that p53 modulation in any context deserves careful human safety evaluation before anyone draws therapeutic conclusions.”
Frequently Asked Questions
What does DRI stand for in FOXO4-DRI?
DRI stands for D-Retro-Inverso. This refers to a two-part engineering modification: all L-amino acids are replaced with their mirror-image D-amino acid counterparts, and the sequence is reversed. This combination gives the peptide near-complete resistance to protease degradation while preserving its binding geometry to the p53 target.
What is the CAS number for FOXO4-DRI?
The CAS number for FOXO4-DRI is 2460055-10-9. It is also known by the trade name Proxofim. Always verify this CAS number against the Certificate of Analysis when sourcing for research use.
How is FOXO4-DRI different from other senolytics like dasatinib and quercetin?
Dasatinib and quercetin work by inhibiting pro-survival pathways that senescent cells depend on, but affect multiple cell types. FOXO4-DRI targets a specific protein-protein interaction – FOXO4 binding to p53 – that is almost exclusively active in senescent cells. This gives FOXO4-DRI higher theoretical selectivity in preclinical models, though no direct head-to-head human data exists.
Has FOXO4-DRI been tested in humans?
No. All published data comes from cell culture and animal studies. There are no completed human clinical trials for FOXO4-DRI. It is classified as a research compound and has not been approved for human therapeutic use by any regulatory authority, including the MHRA in the UK.
What purity should I look for when sourcing FOXO4-DRI?
Research-grade FOXO4-DRI should be verified to at least 98% purity by HPLC and confirmed by mass spectrometry. The D-retro-inverso synthesis is more complex than standard peptide synthesis – a single L-amino acid substitution reintroduces protease susceptibility and undermines the compound’s core advantage. Always request a Certificate of Analysis from any supplier.
Why is FOXO4-DRI used intermittently rather than daily?
Senolytic therapy is conceptually different from daily supplementation. Senescent cells accumulate slowly over weeks and months. Once a cohort is cleared, new senescent cells do not immediately replace them – the clearance effect is durable. This is why the published Baar et al. protocol used a 3-dose alternating-day approach. Continuous daily dosing is not supported by the published literature and is not how the mechanism is designed to work.
FOXO4-DRI from Pure Grade Labs
CAS 2460055-10-9. HPLC verified. Mass spectrometry identity confirmed. Batch-specific COA. UK research chemical supplier.
Summary
FOXO4-DRI (CAS: 2460055-10-9) is the most mechanistically targeted senolytic compound currently available for research use. Its design – D-retro-inverso engineering to create a protease-resistant peptide that disrupts the FOXO4-p53 interaction specifically in senescent cells – is based on a precisely characterised molecular pathway that five independent published studies have confirmed, across skin, kidney, liver, testicular, cartilage, and endothelial tissue models.
The Baar et al. 2017 Cell paper established the mechanism and first in vivo evidence. Zhang et al. 2020 confirmed the selectivity in a testosterone context. Huang et al. 2021 showed the application in joint repair research. The 2025 Frontiers study extended it to vascular biology. The Bourgeois et al. 2025 Nature Communications paper provided the first detailed structural characterisation of the p53-FOXO4-DRI complex. The research record is small but consistent and expanding.
For UK researchers sourcing FOXO4-DRI, the key verification requirements are: CAS 2460055-10-9 on the COA, HPLC purity at 98%+, mass spectrometry identity confirmation, and independent third-party laboratory verification. The D-retro-inverso synthesis is complex – a single L-amino acid substitution reintroduces protease susceptibility. The COA is not optional.
References
- Baar MP et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1):132-147. PMID: 28340339
- Zhang C et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), 12(2):1272-1284. PMC7053614
- Huang Y et al. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology, 9:677576. PMC8116695
- Frontiers in Bioengineering and Biotechnology (December 2025). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.
- Bourgeois et al. (July 2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications.